Opinions
Robert McWhirter
Bellus Health
BLU-T
RISKY
Mar 18, 2019
The outlook is still quite good. People who use their competing chronic cough treatment lose their sense of taste. They are applying now for their drug's use for other conditions.
N/A
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
RISKY
A pharma company working on a new drug for chronic cough. Early testing has produced good effectiveness and no nasty side effects. Tests should be completed within the year. He believes 60 to 300 patients are being tested. They have great potential. A speculative buy. It may become a takeover target.
biotechnology
pharmaceutical
Advertising